Separate retained liver protein from deficient lung protection, then connect genotype, diagnostic testing, fibrosis assessment, surveillance, and treatment.
A low blood protein level can accompany a liver packed with that same protein. Alpha-1 antitrypsin deficiency makes sense only when you separate the protein that fails to leave the hepatocyte from the protection that fails to reach the lung.
The first decision is where the injury occurs. Replacing circulating alpha-1 antitrypsin does not extract abnormal protein from liver cells.
One protein, two destinations
Hepatocytes make most circulating alpha-1 antitrypsin, also called AAT, a protease inhibitor encoded by SERPINA1. Normally, protein processing in the endoplasmic reticulum permits secretion into blood. Functional AAT reaches the lung and limits neutrophil elastase activity. Elastase is useful in host defense, but unchecked proteolysis damages alveolar tissue. The Z protein folds abnormally and forms polymers that are retained in hepatocytes. Intracellular accumulation promotes cellular injury, fibrosis, and eventually cirrhosis in susceptible individuals. [1]
Inside the liver cell
SERPINA1 Z variant → abnormal folding in endoplasmic reticulum → retained polymers → hepatocyte injury and fibrosis.
Toxic gain of function describes the harmful accumulated material.
Beyond the liver cell
Reduced secretion → low functional AAT in blood → less inhibition of neutrophil elastase → alveolar destruction.
Loss of function describes the missing antiprotease protection.
These parallel routes explain why a blood replacement treatment can address a pulmonary deficit without treating intracellular liver retention. The figure depicts mechanisms, not the microscopic appearance of a biopsy.
Panacinar emphysema, often more prominent at the lung bases, is the classic pulmonary association. Neither a smoking history nor a different emphysema distribution excludes AAT deficiency. Testing recommendations extend to all adults with COPD and people with unexplained bronchiectasis, not just young nonsmokers with a textbook scan. A pulmonary diagnosis also creates a reason to assess the liver, even when the patient has never been jaundiced. [2]
The organ distinction prevents a common explanation error. Neutrophil elastase does not account for the characteristic hepatocyte globules. Conversely, describing emphysema as accumulation of hepatic globules in alveoli confuses the two compartments. Ask whether the finding reflects retained material, missing function, or an established complication of fibrosis.
The allele pair predicts risk, not destiny
SERPINA1 expression is autosomal codominant. Both inherited alleles contribute to the protein phenotype. PI*MM usually denotes the common normal protein pattern. PI*ZZ usually causes severe deficiency with a substantial risk of both pulmonary and hepatic disease. PI*MZ is not equivalent to PI*ZZ, but a Z allele can increase susceptibility to liver injury, particularly with other hepatic stressors. The supporting adult case-control evidence concerns NAFLD and chronic alcohol misuse; it is not a prediction of inevitable cirrhosis. [9] PI*SZ has variable expression and requires interpretation alongside protein concentration and organ assessment. [1]
Retention versus absence
Polymer-producing Z alleles can produce the combination of low circulating AAT and retained liver protein.
Null alleles produce no detectable protein from that allele. A person with two null alleles can have profound pulmonary deficiency without the same retained-protein liver mechanism. A very low serum level therefore does not, by itself, rank hepatic polymer burden.
Penetrance is variable. Two relatives with PI*ZZ can have different disease severity, and an adult with liver disease need not have had recognized neonatal hepatitis. Explain risk without predicting inevitable cirrhosis or inevitable emphysema. Avoid using “carrier” to imply that no counseling or organ assessment is needed. Alcohol exposure, obesity, and metabolic liver disease deserve attention alongside the inherited cause. [1][3]
For two PI*MZ parents, each pregnancy independently has a one-in-four probability of PI*ZZ, one-in-two of PI*MZ, and one-in-four of PI*MM. This is allele transmission, not a prediction of when symptoms will occur. An affected person's adult siblings should be offered counseling and testing. Family assessment should identify the familial variant rather than relying only on a serum concentration that overlaps across genotypes. [2]
Confirm the inherited disorder without overlooking cholestasis
In infancy, persistent jaundice with an increased direct or conjugated bilirubin fraction, hepatomegaly, pale stools, or impaired growth requires evaluation for cholestasis. AAT deficiency belongs in that differential, but a known family history must not postpone the time-sensitive assessment of biliary atresia or other treatable causes. Conjugated hyperbilirubinemia is not physiologic newborn jaundice. In adults, unexplained aminotransferase abnormalities, fibrosis, cirrhosis, or portal hypertension may be the first hepatic presentation. [1][7]
Measure serum AAT. Interpret the laboratory's units and reference range. A low level supports deficiency.
Account for inflammation. AAT is an acute-phase reactant. An apparently reassuring concentration during infection can obscure a deficiency phenotype.
Define the inherited cause. Use SERPINA1 genotyping and, when informative, protease inhibitor typing. Common-variant assays do not detect every rare allele.
Resolve discordance. If protein concentration, phenotype, family history, and common-variant results disagree, obtain expanded molecular assessment rather than dismissing the clinical suspicion.
Protein typing describes the circulating protein pattern; genotyping examines the inherited sequence. These are complementary tools, not interchangeable measurements. Molecular findings can establish the inherited allele pair, while the serum measurement characterizes circulating deficiency. Do not tell a family that a valid molecular diagnosis is inherently invalid unless a biopsy is also obtained. The clinical question determines which complementary testing is necessary. [1][2]
What the globules establish
Periodic acid-Schiff staining after diastase digestion can reveal retained glycoprotein as PAS-positive, diastase-resistant hepatocyte inclusions. Diastase digests glycogen; persistence after digestion supports material other than glycogen. AAT immunostaining can help characterize the deposit. Iron stains and Congo red answer different pathology questions.
Biopsy is useful when histology or fibrosis assessment will resolve uncertainty. It is not a routine prerequisite for every diagnosis. Globules are suggestive, not independently diagnostic of a particular allele pair. They may be sparse or absent in young infants, and histology cannot reliably distinguish PI*MZ from PI*ZZ. A negative early biopsy does not exclude the inherited disorder. [1]
Measure damage separately from liver reserve
Aminotransferases reflect injury; they are not a direct measurement of remaining functional liver mass. Albumin, INR, bilirubin, platelet count, examination, imaging, and fibrosis assessment add different information. Falling platelets with splenomegaly can indicate portal hypertension despite modest aminotransferase abnormalities. Ascites, variceal hemorrhage, or hepatic encephalopathy identifies a complication that changes urgency.
The 2026 multisociety consensus favors elastography for fibrosis staging. A vibration-controlled transient elastography liver stiffness of at least 8 kPa is a proposed threshold for clinically significant fibrosis in this setting, not a stand-alone diagnosis of cirrhosis. Low FIB-4 or APRI values can support risk assessment but have limited sensitivity. Normal enzymes or a low blood-based score must not automatically cancel indicated liver evaluation. Interpret noninvasive tests together and investigate discordant results. [3]
Routine organ monitoring
Annual liver-focused assessment is recommended in adult AAT deficiency, with closer review for abnormalities. Include examination, liver laboratory studies, platelets, and ultrasound. Pulmonary assessment includes baseline function testing and subsequent spirometry.
HCC surveillance in cirrhosis
For eligible patients with cirrhosis, generally use ultrasound plus AFP approximately every six months. Child-Pugh C cirrhosis warrants surveillance only when liver transplantation is an option; life-limiting comorbidity can also negate surveillance benefit. This has a different purpose and interval from routine annual AAT follow-up.
HCC surveillance seeks an early tumor; elastography estimates fibrosis. One does not replace the other. Surveillance eligibility depends on liver stage, treatment candidacy, and the applicable cirrhosis guidance, not solely on finding a Z allele. Poor ultrasound visualization or a suspicious lesion may require a different imaging pathway. [2][4]
Protect both organs and recognize the transplant boundary
Care includes smoking cessation and avoidance of secondhand smoke and harmful occupational inhalants. Review alcohol and potentially hepatotoxic products, address metabolic risk factors, and provide hepatitis A and B vaccination when indicated. These actions reduce avoidable injury; they do not correct SERPINA1. Established COPD and cirrhosis still need their usual organ-specific care. A genetic explanation does not replace treatment of ascites, bleeding, infection, or encephalopathy. [1][2]
Intravenous AAT augmentation has a role in selected patients with AAT-related obstructive lung disease. It is not recommended as treatment for AAT-related liver disease because adding normal circulating protein does not clear retained hepatocyte polymers. Nor is the rationale that augmentation has been shown to accelerate hepatic polymerization. Keep the indication and the explanation accurate. [2]
For decompensated hepatic disease, timely transplant evaluation matters. Liver transplantation replaces the failing liver and its abnormal protein production with the donor liver's AAT phenotype. It does not reverse already destroyed alveoli, alter the recipient's inherited genotype in other cells, or remove inherited risk from relatives. [1] TIPS can address selected portal-hypertensive complications but is not a replacement for the failing organ. [8]
Experimental approaches must be distinguished from established treatment. Fazirsiran studies have reduced intrahepatic Z-AAT by suppressing its synthesis. Those biomarker results refute an absolute claim that drug treatment can never reduce deposits, but do not establish routine curative therapy or guarantee improved survival. The placebo-controlled phase 2 study and subsequent trial programs belong in a research discussion, not a prescription presented as standard care. [5][6]
Use the finding to choose the task. Unexplained cholestasis or COPD warrants testing. Discordant tests warrant clarification. Confirmed deficiency warrants assessment of both organs. Fibrosis warrants structured follow-up. Decompensation warrants specialist care and transplant evaluation.
Apply the liver and lung distinction
Case 1
Show answer and explanations for case 1
A. Retention of polymerized AAT in hepatocyte endoplasmic reticulum (Best answer)
The intracellular retained protein produces toxic injury and fibrosis.
B. Unopposed elastase digestion of hepatocytes (Why this does not fit)
Elastase-mediated tissue destruction explains the pulmonary deficit, not these hepatocyte deposits.
C. Autoimmune destruction of small bile ducts (Why this does not fit)
That process would not explain AAT-positive intracellular globules.
D. Deficient bilirubin conjugation (Why this does not fit)
A conjugation defect does not account for cirrhosis with retained AAT.
Takeaway: Localize the abnormal protein before assigning the injury mechanism.
